Nuclear Corp.) and reacting it with the adamantoyl chloride. The product obtained after work-up had a specific activity of 18 μ Ci/mg.

Compounds. The 3-deazauridine used for antitumor evaluation in mice was purchased from the ICN Corp., Irvine, Calif.

Microbial Assays. The procedure used for these assays has been published previously.¹⁷

In Vitro Antitumor Assays. The *in vitro* antitumor assays were carried out by our micro technique whereby 0.5-ml aliquots of medium (RPMI 1630 + 10% calf serum) containing the analog are introduced into 16×125 mm screw cap culture tubes, followed by 0.5-ml portions of the medium containing 3×10^5 L-1210 cells. The cultures are incubated at 37° for 40 hr, after which time the viable cells are counted by Trypan Blue exclusion. During this time, the cell number in the controls increases *ca.* eight- to ninefold with an average cell viability of 99%.

In Vivo Antitumor Assay. On day 0, DBA₂/Ha mice of the same age group (5-7 weeks) were separated into weight groups (17-19 g \pm 0.5 g). The ascites fluid from one or more mice (depending on the number of cells needed) inoculated ip with L-1210 cells 6-7 days prior to experiment was collected and the percentage of viable cells determined by Trypan Blue exclusion. The fluid was diluted with saline so that the 0.5-ml aliquot administered ip to each mouse contained 1×10^6 viable L-1210 cells. On day 1, the animals were randomized into the various test groups, and the deazapyrimidines were injected once daily for 6 consecutive days by the route indicated in Table II.

Biochemical Assays. To examine the cleavage of 4-O-adamantoyl-3-deazauridine, a total of 2 ml of packed L-1210 cells was collected from the intraperitoneal cavity of DBA,/Ha mice. The cells were suspended in 10 ml of 0.05 M phosphate buffer, pH 7.5, and were disrupted by exposure for 1.5 min to a Bronson III sonifier. The cell debris was removed by centrifugation at 19,500g for 30 min, and a 4-ml aliquot of this extract was added to 5 ml of 0.05 M phosphate buffer, pH 7.5, containing 1×10^{-4} M 4-O-adamantoyl-3H-deazauridine (specific activity 18.0 µCi/mg) and 1 ml of $0.1 M MgCl_2$. (Such a large volume was used because of the relative insolubility of the adamantoyl derivative.) The mixture was incubated at 37°, and 1-ml aliquots were removed at stated intervals. They were immersed into boiling water for 2 min, the precipitates which formed were removed by centrifugation, the supernatant solutions were reduced in volume to 0.5 ml, and 0.1-ml portions were applied to Whatman No. 3 paper and were chromatographed together with authentic carriers in 1-butanol-H₂O (86:14) and a solvent prepared by dissolving 13.8 g of Na₂HPO₄·H₂O in 900 ml of H₂O and adjusting the pH to 6.8 with H_3PO_4 . The volume was raised to 1 l. and 600 g of $(NH_4)_2SO_4$ and 20 ml of *n*-PrOH were added. In these two solvent systems the $R_{\rm f}$ of the ester 5 is 0.91 and 0.03 and that of 3deazauridine (4) is 0.44 and 0.50, respectively. Strips 3 cm in width extending from the origin to the solvent front were cut from the chromatogram and were divided into 1-cm segments. Each segment was placed into a scintillation vial to which was added 20 ml of toluene containing 0.4% of 2,5-diphenyloxazole and 0.01% of 1,4bis[2-(4-methyl-5-phenyloxazolyl)]benzene. Radioactivity was measured in a Packard TriCarb Model 3000 liquid scintillation counter. Control experiments were performed by incubating 5 in the same total volume of phosphate buffer, pH 7.5, containing 1 ml of 0.1 M MgCl₂ but no L-1210 cell extract.

Acknowledgments. The authors are grateful to Miss Rosemary Hromchak and Mr. Gary Bruns for their excellent technical assistance and thank Dr. E. Mihich for helpful discussions.

References

- J. Skoda, Progr. Nucl. Acid Res. Mol. Biol., 2, 197 (1963);
 C. E. Hoffmann in "Annual Reports in Medicinal Chemistry, 1967," C. K. Cain, Ed., Academic Press, New York, N. Y., 1968, p 120; G. M. Timmis and D. C. Williams, "Chemotherapy of Cancer," Butterworths, London, 1967.
- (2) M. P. Mertes, J. Zielinski, and C. Pillar, J. Med. Chem., 10, 320 (1967).
- (3) H. Pischel and G. Wagner, Arch. Pharm. (Weinheim), 300, 602 (1967), and references cited therein.
- M. J. Robins and B. L. Currie, Chem. Commun., 1547 (1968);
 M. J. Robins, B. L. Currie, R. K. Robins, and A. Bloch, Proc. Amer. Ass. Cancer Res., 10, 73 (1969).
- (5) (a) B. L. Currie, R. K. Robins and M. J. Robins, J. Heterocycl. Chem., 7, 323 (1970); (b) B. L. Currie, M. J. Robins, and R. K. Robins, *ibid.*, 8, 221 (1971).

- (6) G. L. Neil, P. F. Wiley, R. C. Manak, and T. E. Moxley, *Cancer Res.*, 30, 1047 (1970).
- (7) G. Errera, Ber., 31, 1682 (1898).
- (8) J. Baumler, E. Sorkin, and H. Erlenmeyer, *Helv. Chim. Acta*, 34, 496 (1951).
- (9) R. J. Rousseau and R. K. Robins, J. Heterocycl. Chem., 2, 196 (1965).
- (10) H. J. den Hertog and D. J. Buurman, Recl. Trav. Chim. Pays-Bas, 75, 257 (1956).
- (11) M. J. Robins, B. L. Currie, R. K. Robins, and A. D. Broom, *Can. J. Chem.*, 49, 3067 (1971).
- (12) A. Albert and J. N. Phillips, J. Chem. Soc., 1294 (1956).
- (13) J. Hine, "Physical Organic Chemistry," McGraw-Hill, New York, N. Y., 1956, pp 274-275.
- (14) A. Albert, R. Goldacre, and J. N. Phillips, J. Chem. Soc., 2240 (1948).
- (15) M. C. Wang and A. Bloch, Biochem. Pharmacol., 21, 1063 (1972).
- (16) A. Bloch, G. Dutschman, and G. Grindey, Proc. Amer. Ass. Cancer Res., 13, 19 (1972).
- (17) A. Bloch and C. Coutsogeorgopoulos, *Biochemistry*, 5, 3345 (1966).

Synthesis and Anticoccidial Activity of 3-Fluoro-5chloro- and -bromo-2,6-dimethyl-4-pyridinol

Lowell D. Markley* and Michael K. Eckman


Ag-Organics Department, The Dow Chemical Company, Midland, Michigan 48640, Received August 18, 1972

3,5-Dichloro-2,6-dimethyl-4-pyridinol (clopidol, 1) is the active component in the coccidiostat, COYDEN, sold by The Dow Chemical Co.^{1,2} Other 3,5-dihalo-2,6-dimethyl-4-pyridi-



nols including 3,5-dibromo, 3,5-diiodo, and 3-bromo-5-chloro have been synthesized and shown to have good anticoccidial activity.¹ Since many biologically active chemicals contain fluorine, it was of interest to synthesize several 3-fluoro-4pyridinols and test them for possible anticoccidial activity.


The 3,5-dichloro-, 3,5-dibromo-, and 3,5-diiodo-2,6dimethyl-4-pyridinols have been synthesized by halogenation of 2,6-dimethyl-4-pyridinol with chlorine,² bromine,³ and



iodine chloride,⁴ respectively. The synthesis of the fluoro derivatives has required the use of a more indirect approach since fluorination of 2,6-dimethyl-4-pyridinol did not seem feasible.

In 1965, Talik and coworkers⁵ reported synthesizing 4chloro-3-fluoro-2,6-lutidine (6). From this compound, we were able to prepare our desired fluoro-substituted pyridinols. Talik's synthesis of 6 (Scheme I) was utilized with several modifications as given in the Experimental Section. Treatment of 3-fluoro-4-nitro-2,6-lutidine 1-oxide (5) with phosphorous trichloride gave 4-nitro-3-fluoro-2,6-lutidine (7), previously not reported by Talik, in addition to the desired 4-chloro-3-fluoro-2,6-lutidine (6). The two materials were readily separated νia distillation.






From 4-chloro-3-fluoro-2,6-lutidine (6) we synthesized the desired 3-chloro-5-fluoro-2,6-dimethyl-4-pyridinol (10) and 3-bromo-5-fluoro-2,6-dimethyl-4-pyridinol (11) *via* halo-

5
$$\xrightarrow{PCl_3}_{\Delta}$$
 6 + $\xrightarrow{NO_2}_{CHCl_3}$ F
 CH_3 N CH₃

genation as outlined in Scheme II. Nucleophilic displacement of the 4-chloro group in 6 with 1 equiv of sodium methoxide took place readily at 130° giving 3-fluoro-4-methoxy-2,6lutidine (8). Demethylation of 8 was attempted using three different reagents: boron tribromide, hydriodic acid, and sodium methoxide. A quantitative yield of demethylated product, 4-hydroxy-3-fluoro-2,6-lutidine (9), was obtained with excess sodium methoxide at 190°. From 9, the desired products, 10 and 11, were formed by chlorination and bromination, respectively.

Anticoccidial Activity. 3-Chloro-5-fluoro-2,6-dimethyl-4-pyridinol (10) and 3-bromo-5-fluoro-2,6-dimethyl-4-pyridinol (11) were tested against two strains of coccidiosis, *Eimeria necatrix* and *Eimeria acervulina*, using the method given in ref 1. As shown in Table I, both compounds showed activity equal to clopidol (1) against *E. necatrix* but little or no activity against *E. acervulina* at comparable concentrations.

Scheme II. Synthesis of 3,5-Dihalo-2,6-dimethyl-4-pyridinols (10 and 11)



Experimental Section

Melting points were determined with a Thomas-Hoover capillary melting point apparatus and are uncorrected. Ir spectra were recorded

Table I. Activity of Compounds 10 and 11 and Clopidol

No.	Per cent control of coccidiosis ^a			
	E. necatrix		E. acervulina	
	125 ppm	250 ppm	125 ppm	250 ppm
10	100	100	0	0
11	100	100	0	70
Clopidol	100	100	95	100

^{*a*}Anticoccidial index = % weight gain – (sum of the mean fecal and lesion scores). % coccidiosis control = (anticoccidial index of experimental group/anticoccidial index of uninoculated-unmedicated control)100.

on an Infracord spectrophotometer and nmr on a Varian Associates A-60 instrument (Me₄Si) and are in accord with proposed structures. Elemental analyses were obtained on new compounds 9, 10, and 11 and the results were within $\pm 0.3\%$ of the theoretical values of those elements indicated by symbols.

3-Fluoro-2,6-lutidine 1-Oxide (4). To 105 g (0.84 mol) of 3 dissolved in 500 ml of glacial AcOH was added 210 g (1.1 mol of peroxide) of 40% peracetic acid. The reaction mixture was heated at $75-78^{\circ}$ for 12 hr and the solvent was then removed *in vacuo*. The liquid residue remaining was dissolved in 400 ml of CH₂Cl₂ and extracted with saturated NaHCO₃ and removal of solvent gave a quantitative yield of hydrated 4, mp ~15-20°, which was used without purification. Bellas and Suschitzky⁶ reported obtaining the pentahydrate, mp 53°.

4-Chloro-3-fluoro-2,6-lutidine (6) and 4-Nitro-3-fluoro-2,6-lutidine (7). To 114 g (0.615 mol) of 5 dissolved in 250 ml of $CHCl_3$ was added 25° ml (2.86 mol) of PCl_3 . After heating the mixture for 3 hr at 65-70° and removal of solvent *in vacuo*, the liquid residue was slowly poured over 600 ml of ice. Neutralization (K_2CO_3) caused precipitation of an immiscible layer which was steam distilled and extracted with CH_2Cl_2 . Evaporation of solvent *in vacuo* afforded 84.6 g of liquid which upon distillation gave 48.7 g (50%) of 6 [bp 90-93° (42 mm), $n^{24-5}D$ 1.5006 (lit.⁵ bp 174-175°)] and 30.3 g (29%) of 7, bp 113° (16 mm).

4-Methoxy-3-fluoro-2,6-lutidine (8). In a stainless-steel bomb was placed 40 g (0.25 mol) of 6 in 50 ml of MeOH and 100 ml of 2.6 N NaOCH₃-MeOH. After heating for 7 hr at 130°, the contents of the bomb were poured into 200 ml of H₂O. Extraction with CH₂Cl₂ afforded 37.7 g of liquid shown by nmr to be 92% 8 and 8% starting material 6. The product was used without purification since in the next step the starting material 6 is used up.

4-Hydroxy-3-fluoro-2,6-lutidine (9). In a stainless-steel bomb was placed 28 g of 8 and 150 ml of 5 N NaOCH₃-MeOH and the bomb was heated at 190° for 17 hr. The contents of the bomb were poured into 200 ml of H₂O and 100 ml of MeOH. The solution was neutralized (concentrated H_2SO_4) and the solvent removed *in vacuo* leaving a solid residue which was triturated with 400 ml of boiling MeOH. The filtrate yielded 25 g (98%) of 9, mp 248° dec. Sublimation [125° (0.2 mm)] gave pure product, mp 259° dec. Anal. (C₂H₈FNO) C, H, N.

3Chloro-5-fluoro-2,6-dimethyl-4-pyridinol (10). Into a solution of 10 g of 9, dissolved in 50 ml of H₂O and 25 ml of 5 N HCl, was bubbled Cl₂ gas with precipitation of product. The reaction mixture was neutralized (K₂CO₃) and the product 10 was filtered and washed with H₂O and Me₂CO, 4.2 g (34%). Sublimation [150° (0.2 mm)] gave pure product, mp >360°. Anal. (C₂H₂CIFNO) C, H, N.

3-Bromo-5-fluoro-2,6-dimethyl-4-pyridinol (11). To 10 g of 9 dissolved in 75 ml of glacial AcOH was added 11.7 g of Br_2 dissolved in 20 ml of glacial AcOH. After stirring 2 hr, the product was filtered and washed with H_2O and Me_2CO : 6.1 g (39%), mp 270° dec. Recrystallization (DMF) gave pure 11, mp 284-286° dec. *Anal.* (C₂H₂BrFNO) C, H, N.

References

- (1) G. T. Stevenson, U. S. Patent 3,206,358 (1965).
- (2) R. H. Rigterink, U. S. Patent 3,246,001 (1966).
- (3) M. Conrad and M. Guthzeit, Chem. Ber., 20, 154 (1887).
- (4) E. Ochiai and M. Fujimoto, Chem. Pharm. Bull., 2, 131 (1954).
- (5) Z. Talik, T. Talik, and A. Puszynski, Rocz. Chem., 39, 601
- (1965); Chem. Abstr., 63, 16298 (1965).
- (6) M. Bellas and H. Suschitzky, J. Chem. Soc., 2096 (1965).